A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00358553
- Lead Sponsor
- Baxter Healthcare Corporation
- Brief Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Healthy Male Subjects
- Age between 18 and 40 years of age
Exclusion Criteria
- History of Diabetes
- Subjects with clinically significant active disease
- Known allergy to insulin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of recombinant human insulin in regulating blood glucose levels?
How does recombinant human insulin compare to animal-derived insulin in pharmacokinetic profiles?
What biomarkers are associated with optimal response to recombinant human insulin therapy?
What are the potential adverse events of recombinant human insulin and how are they managed?
Are there combination therapies involving recombinant human insulin for diabetes management?
Trial Locations
- Locations (1)
Profil
🇩🇪Neuss, Germany
Profil🇩🇪Neuss, Germany